Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimegepant ODT for Acute Migraine
NCT03461757Phase 3Completed
- Sponsor
- Pfizer
- Start
- Feb 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Rimegepant 75 mg with Placebo (2 arms). Primary endpoints: Percentage of Participants With Freedom From Pain at 2 Hours Post-dose and Percentage of Participants With Freedom From Most Bothersome Symptom (MBS) at 2 Hours Post-dose. Started Feb 2018; status: completed.
02
Drugs
rimegepant
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03461757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03461757.